Agile Therapeutics (NASDAQ:AGRX)‘s stock had its “buy” rating reaffirmed by equities researchers at Noble Financial in a report released on Wednesday.
AGRX has been the topic of several other reports. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Agile Therapeutics in a report on Tuesday. Janney Montgomery Scott lowered shares of Agile Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 28th. William Blair lowered shares of Agile Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 26th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $5.00 target price on shares of Agile Therapeutics in a report on Friday, December 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. Agile Therapeutics has a consensus rating of “Hold” and a consensus target price of $9.00.
Agile Therapeutics (AGRX) traded down $0.18 during trading hours on Wednesday, reaching $3.19. 141,010 shares of the company were exchanged, compared to its average volume of 211,594. Agile Therapeutics has a 1-year low of $1.93 and a 1-year high of $5.60. The company has a market capitalization of $117.81, a price-to-earnings ratio of -3.47 and a beta of 1.91.
Institutional investors and hedge funds have recently bought and sold shares of the company. Royal Bank of Canada boosted its stake in shares of Agile Therapeutics by 608.0% in the 2nd quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after purchasing an additional 27,907 shares in the last quarter. OxFORD Asset Management LLP acquired a new stake in shares of Agile Therapeutics in the 3rd quarter valued at approximately $161,000. Bank of New York Mellon Corp boosted its stake in shares of Agile Therapeutics by 113.1% in the 4th quarter. Bank of New York Mellon Corp now owns 38,920 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 20,654 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Agile Therapeutics in the 2nd quarter valued at approximately $309,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Agile Therapeutics by 604.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after purchasing an additional 82,213 shares in the last quarter. Institutional investors own 67.34% of the company’s stock.
WARNING: This piece of content was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.thelincolnianonline.com/2018/03/15/noble-financial-reaffirms-buy-rating-for-agile-therapeutics-agrx.html.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.